CAR-T细胞与异基因移植治疗晚期大B细胞淋巴瘤的意向性治疗比较
该研究以意向性治疗(ITT)比较CAR-T细胞与异基因造血干细胞移植(alloHCT)作为复发/难治大B细胞淋巴瘤标准治疗的结果。纳入CAR-T意向41例、alloHCT意向60例,中位OS分别为475天与285天(P=.88);结论认为CAR-T疗效不劣于alloHCT,支持优先选择CAR-T作为首次细胞免疫治疗。
要点
- ITT分析中CAR-T与alloHCT中位OS无显著差异(475天 vs 285天,P=.88)。
- CAR-T组12个月非复发死亡率显著低于alloHCT组(3% vs 21%,P=.04)。
- 结果支持将CAR-T作为多次复发/难治LBCL首次细胞免疫治疗的优先选择。
核心结论
- 无论按ITT还是从细胞免疫治疗实施后分析,CAR-T细胞治疗的结局不劣于alloHCT。
- 结果支持在多次复发/难治大B细胞淋巴瘤中优先选择CAR-T而非alloHCT作为首次细胞免疫治疗。
研究设计与样本
- 单中心回顾性意向性治疗比较研究。
- 纳入2018年7月至2020年2月肿瘤委员会推荐标准治疗CAR-T的R/R LBCL患者41例。
- 纳入2004年1月至2020年2月推荐alloHCT的R/R LBCL患者60例。
- 主要终点为自适应证确立起的总体生存(OS)。
主要发现
- CAR-T意向组与alloHCT意向组自适应证起中位OS分别为475天与285天(P=.88)。
- 二线以后推荐alloHCT的39例患者中位OS为222天(与CAR-T组比较P=.08)。
- CAR-T组与alloHCT组分别有73%与65%的患者实际接受细胞免疫治疗。
- 细胞免疫治疗后12个月非复发死亡率CAR-T组3% vs alloHCT组21%(P=.04)。
- 细胞免疫治疗后12个月复发率59% vs 44%(P=.12),无进展生存39% vs 33%(P=.97),OS 68% vs 54%(P=.32)。
临床怎么用
- 对于多次复发/难治大B细胞淋巴瘤,可优先考虑CAR-T细胞治疗作为首次细胞免疫治疗。
- alloHCT仍可作为细胞免疫治疗选择之一,但需权衡其较高的非复发死亡率。
局限性
- 研究为单中心回顾性设计,样本量较小(CAR-T组41例,alloHCT组60例)。
- 两组纳入时间跨度不同(CAR-T组2018–2020年,alloHCT组2004–2020年),可能存在时代偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CD19-directed chimeric antigen receptor (CAR) T-cell treatment has evolved as standard of care (SOC) for multiply relapsed/refractory (R/R) large B-cell lymphoma (LBCL). However, its potential benefit over allogeneic hematopoietic cell transplantation (alloHCT) remains unclear. We compared outcomes with both types of cellular immunotherapy (CI) by intention to treat (ITT). Eligble were all patients with R/R LBCL and institutional tumor board decision recommending SOC CAR T-cell treatment between July 2018 and February 2020, or alloHCT between January 2004 and February 2020. Primary end point was overall survival (OS) from indication. Altogether, 41 and 60 patients for whom CAR T cells and alloHCT were intended, respectively, were included. In both cohorts, virtually all patients had active disease at indication. CI was recommended as part of second-line therapy for 21 alloHCT patients but no CAR T-cell patients. Median OS from indication was 475 days with CAR T cells vs 285 days with alloHCT (P = .88) and 222 days for 39 patients for whom alloHCT beyond second line was recommended (P = .08). Of CAR T-cell and alloHCT patients, 73% and 65%, respectively, proceeded to CI. After CI, 12-month estimates for nonrelapse mortality, relapse incidence, progression-free survival, and OS for CAR T cells vs alloHCT were 3% vs 21% (P = .04), 59% vs 44% (P = .12), 39% vs 33% (P = .97), and 68% vs 54% (P = .32), respectively. In conclusion, CAR T-cell outcomes were not inferior to alloHCT outcomes, whether measured by ITT or from CI administration, supporting strategies preferring CAR T cells over alloHCT as first CI for multiply R/R LBCL.
引用
- Dreger P, Dietrich S, Schubert ML, et al. CAR T cells or allogeneic transplantation as standard of care for advanced large B-cell lymphoma: an intent-to-treat comparison. Blood Adv. 2020. PMID: 33351108. doi:10.1182/bloodadvances.2020003036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。